Datscan progression in PD (Simuni 2018 #2272 Table 5 baseline-Month 6/12/24/48; Table 7s Year 1/Year 4 percent change), Arthur volcano AD-PD database mining longitudinal DaT trajectories + power analysis evidence panels, Kim 2018 review Table 1 Previous Longitudinal Studies of DAT Imaging in PD Patients (Marek/Seibyl references), Correlation between Datscan & MDS-UPDRS opener (TABLE 4B Spearman correlations)

Datscan progression in PD (continued)

(Simuni, 2018 #2272) — change in DAT binding was greatest at year 1 when compared with years 2 and 4. (reason: DAT terminal have largely disappeared by year 4 of diagnosis)

Below table:

(2018 Simuni, PPMI) 대략 인 10% 씩 주네!

The change was greater in ipsilateral putamen than the change in contralateral putamen at all time points, suggesting that there may be a floor effect, limiting the already reduced contralateral putamen.

(Simuni, 2018 #2272) Table 5. Clinical characteristics and DATSCAN over time in PD patients

Variables	Baseline	Month 6	Month 12	Month 24	Month 48	Time-effect
Contralateral putamen
Mean putamen
Contralateral caudate
Mean caudate
Mean striatum

(Simuni, 2018 #2272) Table 7s. Percent Change in DATSCAN over Time in PD Subjects

Variable	% Change at Year 1	% Change at Year 4
Contralateral Putamen	N Completed: 305 / Mean (SD): -13.74 (10.5)	N Completed: 245 / Mean (SD): -71.95 (15.66)
Mean Putamen	N Completed: 305 / Mean (SD): -13.62 (10.7)	N Completed: 245 / Mean (SD): -71.95 (15.66)
Mean Caudate	N Completed: 305 / Mean (SD): -9.54 (10.7)	N Completed: 245 / Mean (SD): -25.17 (15.66)
Mean Striatum	N Completed: 305 / Mean (SD): -10.05 (10.7)	N Completed: 245 / Mean (SD): -25.17 (15.66)

Arthur volcano AD-PD (Simen AAA 18-Apr-2018, S pots)

II. Database mining: Longitudinal Trajectories of DaT signal.

II. DaT Scan Power analysis for each endpoint and time point.

Bullets visible alongside the panels:

• The average straight line is fine and endpoint with respect to power
• A sample size of N=70 patients (TR=14μmol)/min is sufficient at 12 months to detect a 95% reduction in DaTscan decline using a one-sided test with α-significance of 0.05.

(Jpod review used by chajn Kim 2018 #2018)

Table 1. Previous Longitudinal Studies of DAT Imaging in PD Patients

Reference No.	Date	DAT imaging	Patient number, controls in baseline	Mean PD duration in disease (years)	Mean change in monthly score	Mean rate of decline in striatum (%)	Decline pattern

References:

• 25. Marek K. Seibyl J. Eberly S, et al; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82: 1791-1797, 2014
• 26. Seibyl J, Jennings D, Marek K. Assessment of Parkinson disease progression using 123-I-iofupane SPECT: update from Parkinson Progression Marker Initiative Trial (S40.003). Neurology 84 (14 Suppl), 2015
• 27. (2018 Simuni, PPMI)

Correlation between Datscan & MDS-UPDRS

Cross sectional, there is a correlation. (n=18 mds-UPDRS III score(?) 다 correlation 함)

TABLE 4B. Correlations between MDS-UPDRS and DATSCAN SBR (all patients) — Spearman correlations

	Year 0		Year 1		Year 2		Year 4
	r	p	r	p	r	p	r	p
Correlation with mean putamen MDS-UPDRS part III score	-.2760	<.0001	-.2130	.0001	-.2513	<.0001	-.1722	.0243
MDS-UPDRS total score	-.2894	<.0001	-.2511	<.0001	-.3398	<.0001	-.2384	.0017
Correlation with mean caudate MDS-UPDRS part III score	-.1709	.0004	-.1210	.0324	-.1664	.0070	-.1900	.0128
MDS-UPDRS total score	-.1820	.0002	-.1483	.0086	-.2655	<.0001	-.2356	.0019

Uncertain Spans

location	transcription	uncertainty
Simuni 2018 Table 5 cell	most numerical values are partially clipped	preserved as evidence reference.
Kim 2018 Table 1	most cells partially clipped	preserved as evidence reference.